Amgen's Imlygic 1st FDA-Approved Oncolytic Virus Therapy
This article was originally published in Scrip
Executive Summary
Amgen Inc. made history on Oct. 27 by gaining the FDA's approval for the first oncolytic virus therapy – Imlygic (talimogene laherparepvec), which is indicated as a local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.
You may also be interested in...
R&D Head Sean Harper On Amgen's Long-Term Investment View
Amgen is validating targets through the deCODE Genetics investment it made five years and moving drugs into the clinic. It's one of multiple technologies – along with its BiTE and oncolytic virus platforms – that R&D head Sean Harper said is starting to bear fruit for the company.
How To Get Ahead In The Trendy World Of Immuno-Oncology
With basic research in immuno-oncology still very limited, there are still a lot of opportunities to develop new breakthrough therapies beyond checkpoint inhibitors, companies active in the space said during a panel at the recent Biotech Showcase.
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.